Fineline Cube

Follow:
14691 Articles
anatlas Pharmaceuticals Doses First Patient in Phase II Trial of DAT‑2645 – Novel Targeted Therapy for BRCA‑Mutant, HRD‑Positive Ovarian Cancer
CompanyDrug

Danatlas Pharmaceuticals Doses First Patient in Phase II Trial of DAT‑2645 – Novel Targeted Therapy for BRCA‑Mutant, HRD‑Positive Ovarian Cancer

Danatlas Pharmaceuticals Wins NMPA IND Approval for DAT‑6618 – China's First PPARγ Inhibitor to Enter Clinical Development
CompanyDrug

Danatlas Pharmaceuticals Wins NMPA IND Approval for DAT‑6618 – China’s First PPARγ Inhibitor to Enter Clinical Development

Ribo Life Science Opens Automated Intelligent Drug Screening Center – A Key Leap in AI‑Powered siRNA Drug Discovery
Company

Ribo Life Science Opens Automated Intelligent Drug Screening Center – A Key Leap in AI‑Powered siRNA Drug Discovery

CSPC to Unveil Data From 8 Oncology Trials at ESMO Congress 2026 – Anbenitamab Phase III Results Headline Two Late‑Breaking Abstracts
CompanyDrug

CSPC to Unveil Data From 8 Oncology Trials at ESMO Congress 2026 – Anbenitamab Phase III Results Headline Two Late‑Breaking Abstracts

FDA Approves Priovant's LISRAYA (Brepocitinib) for Adult Dermatomyositis – First Oral Targeted JAK1/TYK2 Therapy in the Indication
CompanyDrug

FDA Approves Priovant’s LISRAYA (Brepocitinib) for Adult Dermatomyositis – First Oral Targeted JAK1/TYK2 Therapy in the Indication

AnnJi Advances AJ201 into Pivotal Phase 3 ROMA‑KD Trial – The Only Investigational Therapy for SBMA in Late‑Stage Development Worldwide
CompanyDrug

AnnJi Advances AJ201 into Pivotal Phase 3 ROMA‑KD Trial – The Only Investigational Therapy for SBMA in Late‑Stage Development Worldwide

Asymchem's Tianjin Macromolecule Site Passes First FDA Pre‑Approval Inspection – EIR Issued for Commercial API Facility
Company

Asymchem’s Tianjin Macromolecule Site Passes First FDA Pre‑Approval Inspection – EIR Issued for Commercial API Facility

Pfizer's Oral Ritlecitinib Meets Primary Endpoints in Phase III Nonsegmental Vitiligo Trials – Largest‑Ever Oral Systemic Program Clears Path for Global Filings
CompanyDrug

Pfizer’s Oral Ritlecitinib Meets Primary Endpoints in Phase III Nonsegmental Vitiligo Trials – Largest‑Ever Oral Systemic Program Clears Path for Global Filings

Qyuns Therapeutics' Oturkibart Delivers Late‑Breaking Phase III Data in Prurigo Nodularis at EADV 2026 – IL‑4Rα Antibody Beats Placebo on Itch and Lesion Clearance
CompanyDrug

Qyuns Therapeutics’ Oturkibart Delivers Late‑Breaking Phase III Data in Prurigo Nodularis at EADV 2026 – IL‑4Rα Antibody Beats Placebo on Itch and Lesion Clearance

Abogen Biosciences Strikes Licensing and Option Deal with Novartis for ABO2203 – Up to $7.2 Billion to Advance the First mRNA‑Encoded T‑Cell Engager in Autoimmune Disease
CompanyDeals

Abogen Biosciences Strikes Licensing and Option Deal with Novartis for ABO2203 – Up to $7.2 Billion to Advance the First mRNA‑Encoded T‑Cell Engager in Autoimmune Disease

Shandong Lukang Wins NMPA Registration for Generic Cefuroxime Sodium for Injection – Entering a RMB 2.6 Billion Chinese Cephalosporin Market
CompanyDrug

Shandong Lukang Wins NMPA Registration for Generic Cefuroxime Sodium for Injection – Entering a RMB 2.6 Billion Chinese Cephalosporin Market

Xunfei Healthcare Establishes Hainan Xunfei Internet Hospital Subsidiary with RMB 10 Million Registered Capital – Extending Digital Healthcare Footprint in Hainan Free Trade Port
CompanyHospital

Xunfei Healthcare Establishes Hainan Xunfei Internet Hospital Subsidiary with RMB 10 Million Registered Capital – Extending Digital Healthcare Footprint in Hainan Free Trade Port